Studies supported by the APGI BioResource

Fostering Worldwide Collaboration for Precision Research

The Avner APGI BioResource is one of the largest resources of pancreatic cancer research biomaterials in the world and available to the scientific community. The tables below identify recent projects we have supported.

Current studies

Project TitleIdentification of En2 as a Marker for Early-Stage Detection of Tumours in the Pancreas
SummaryDetecting cancer at an advanced stage limits the effectiveness of current treatments. We have identified a protein, Engrailed 2 (En2), that appears to act as a marker for cancer, and is expressed at relatively high levels in prostate cancer and pancreatic cancer cell lines. We would like to investigate whether the expression of this marker does correlate with the incidence of pancreatic cancer. This project will verify the presence of En2 in pancreatic tumour biopsies via IHC and evaluate its efficacy as a tumour biomarker.
Chief InvestigatorA/Prof Louise Lutz-Mann
InstitutionCancer Research Group, UNSW, Australia
Project TitleAn Exploratory Text Mining Analysis of Clinical Syndromes Associated with Somatic Genomic Aberrations in Pancreatic Cancer.
SummaryWe will apply cutting-edge informatic methods to systematically unfold links between tumour genomics and clinical presentations. We will carry out “big data” analysis that integrates the cancer genomics data and the corresponding clinical records collected as part of the APGI. Our goal is to identify novel genes and gene groups that may help explain both common and idiosyncratic presentations in patients who suffer from pancreatic cancer.
Chief InvestigatorDr Frank Lin
InstitutionKinghorn Cancer Centre for Clinical Genomics, Garvan Institute, Australia
Project TitleAssessing the prognostic/predictive value of SLC7A11 and MutY-Homolog Expression in Human Pancreatic Cancer Cells and Cancer-Associated Pancreatic Stellate Cells.
SummaryWe have identified two proteins that, when inhibited, can kill pancreatic cancer cells and cancer-promoting pancreatic stellate cells and increase the effectiveness of existing cancer drugs. This project will assess whether these proteins are also potential prognostic/predictive factors for pancreatic cancer. The findings from this project can potentially be applied to personalise medicine for pancreatic cancer patients.
Chief InvestigatorDr Phoebe Phillips
InstitutionLowy Cancer Research Centre, UNSW, Australia

Previously supported studies

 

Novel diagnostic and prognostic biomarker panel in blood for pancreatic cancer. Prof Roland Andersson, Lund University, Sweden. March 2016.
Immune phenotyping of pancreatic cancer. Dr David Chang, University of Glasgow UK. March 2016
Targeting stroma and specific ECM components uncouples pancreatic cancer progression, chemo-resistance and the onset of the metastatic niche. Dr Marina Pajic, Garvan Institute of Medical Research, Sydney. February 2016.
Systems Biology analysis of Epithelial-Mesenchymal Transition in pancreatic cancer. Dr Shivashankar Hiriyur Nagaraj, Queensland University of Technology, Brisbane. February 2016.
Immunohistochemistry and Molecular Pathology of Pancreatic Neuroendocrine Tumours and Survival. Dr Ruelan Furtado, Royal Prince Alfred Hospital, Sydney. January 2016.
Cross-talk between myeloid-cells and pancreatic tumor cells by exosome release to promote distal metastatic process (AIRC 5x1000 Italian grant). Dr Vincenzo Bronte, University and Hospital of Verona, Italy. October 2015.
Organotypic cultures with primary cell lines. Professor Hemant Kocher, Barts Cancer Institute, London UK. October 2015.
Tumour-stroma signalling in pancreatic cancer. Dr Claus Jorgensen, Cancer Research UK Manchester Institute, University of Manchester UK. October 2015.
Clinical utility of the GPC-1 ELISA in the early detection of pancreatic cancer. Dr Bradley Walsh, Minomic International Ltd. Sydney. September 2015.
A feasibility study for molecular phenotype driven clinical care for PDAC (PRECISION-Panc). Professor Andrew Biankin, Wolfson Wohl Cancer Research Centre, Glasgow UK. September 2015.
Stratification of the cancer genomic landscape through the development of a pan-cancer gene panel. A/Professor Marcel Dinger, Kinghorn Centre for Clinical Genomics, Sydney. August 2015.
Evaluation of axon guidance protein expression by immunohistochemistry and correlation with clinical and genomic data in pancreatic cancers. Dr Lorraine Chantrill, Garvan Institute of Medical Research, Sydney. June 2015.
Germline RNF43 mutations in pancreatic ductal adenocarcinoma. Dr Douglas Taupin, The Canberra Hospital, ACT. June 2015.
Targeting cancer stem cells in pancreatic cancer (PC): Understanding how stem cells effect cancer cell growth, metastasis and chemoresistance using disulfiram. Dr Marina Pajic, Garvan Institute of Medical Research, Sydney. April 2015.
Determine the frequency and significance of 'Elevated microsatellite alterations at selected tetranucleotide repeats' (EMAST) in pancreatic cancer. A/Professor Maija Kohonen-Corish, Garvan Institute of Medical Resarch, Sydney. April 2015.
Targeting resectable Pancreatic Adenocarcinoma Actionable Genes with FDA-Approved Drugs. Dr Francis Brunicardi, UCLA, California USA. March 2015.
Studying effectors of TGFb signaling in pancreatic cancer. Professor Owen Sansom, Cancer Research UK Beatson Institute, Glasgow UK. February 2015.
Molecular mechanisms of pancreatic cancer progression and metastasis. Dr Paola Martinelli, Institute for Cancer Research, Medical University Vienna, Italy. December 2014.
The relationship between the HGF/c-Met pathway and patient outcome in patients with pancreatic adenocarcinoma. Dr Adnan Nagrial, Garvan Institute of Medical Research, Sydney. October 2014.
microRNAs as prognostic biomarkers for pancreatic ductal adenocarcinoma. Dr Karin Oien, University of Glasgow UK. October 2014.
An investigation of the impact of clinicopathological factors on the pattern of recurrence following resection for pancreaticobiliary malignancy. David Chang, Garvan Institute of Medical Research, Sydney. June 2014.
Novel Therapeutic Strategies Targeting Aberrant Cell Cycle Regulation in pancreatic cancer. Angela Chou, Garvan Institute of Medical Research, Sydney. April 2014.
Assessment of ATM as a potential biomarker of DNA-damaging agents responsiveness. Dr David Chang, Garvan Institute of Medical Research, Sydney. April 2014.
Defining gemcitabine responsiveness biomarkers in pancreatic cancer. Dr David Chang, Garvan Institute of Medical Research, Sydney. February 2014.
Evaluation of B-catenin protein expression and correlation with robo/Slit expression by immunohistochemistry in human pancreas cancers. Dr Lorraine Chantrill, Garvan Institute of Medical Research, Sydney. January 2014.
Defining 5-FU responsive phenotypes in pancreatic cancer based on CDX2 and MUC1 expression. Dr Adnan Nagrial, Garvan Institute of Medical Research, Sydney. January 2014
Investigating CXCR2 signalling in pancreatiitis. Dr Colin Steele, Beatson Institute for Cancer Research, Glasgow UK. January 2014.
Germline Mismatch Repair Mutations in Pancreatic Cancer. Dr Jeremy Humphris, Garvan Institute of Medical Research, Sydney. January 2014.
Defining Abraxane responsive phenotypes in pancreatic cancer based on SPARC expression. Dr Marina Pajic, Garvan Institute of Medical Research, Sydney. December 2013.
Determination of the connection between the activity and expression of PAK1 and PAK4 and response to chemotherapy and survival in patients with pancreatic cancer. Mr Mehrdad Nikfarjam, University of Melbourne VIC. December 2013.
The prognostic relevance of EGFR expression in pancreatic cancer. Dr Marina Pajic, Garvan Institute of Medical Research, Sydney. October 2013.
Potential role of Ki-67 as an prognostic factor of pancreatic SPTs: a systematic review. Feng Yang Huashan Hospital, Shanghai Medical College, Fudan University, China. June 2013
Circulating DNA as a personalized biomarker for patients with pancreatic cancer. Kelly Quek, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, Brisbane. May 2013.
Genotype-guided personalized therapy for pancreatic cancer. Professor Andrew Biankin, Wolfson Wohl Cancer Research Centre, University of Glasgow UK. May 2013.
Surgical treatment of pancreatic endocrine tumours in NSW. Charbel Sandroussi, University of Sydney Medical Program, Royal Prince Alfred Hospital, Sydney. May 2013.
The Cancer Genome Atlas (TCGA). National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) USA. April 2013.
ROCK 1 as a targetable phenotype for pancreatic cancer. Venessa Chin, Garvan Institute of Medical Research Sydney. February 2013.
Integrated meta analysis of pancreatic ductal adenocarcinoma studies towards prognostic biomarker discovery. Dr Claude Chelala, Barts Cancer Institute, Queen Mary University of London UK. January 2013.
The regulatory loop of Sirt1, Dbc1 and Myc in pancreatic cancer. Ilse Rooman, Garvan Institute of Medical Research Sydney. January 2013.
Assessment of the incidence and clinical significance of the FIG-ROS1 fusion oncogene in tumours presenting as pancreatic carcinoma (including extrahepatic cholangiocarcinomas). Anthony Gill, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney. January 2013.
Models to understand the role of menin in mammalian development and endocrine neoplasia. Kelly Loffler, Queensland Institute of Medical Research, Brisbane. September 2012.
Role of Sox9 in pancreatic carcinogenesis. Andreia Pinho, Garvan Institute of Medical Research, Sydney. August 2012.
Analysis of differential protein expression by immunohistochemistry of key targets in paired sets of primary and metastatic pancreatic cancer from 8 patients. Dr Lorraine Chantrill, Garvan Institute of Medical Research, Sydney. July 2012.
Outcomes of second line palliative chemotherapy in pancreatic adenocarcinoma. Dr David Goldstein, Prince of Wales Hospital, Sydney. July 2012.
Cystic Neoplasms of the pancreas: Trends over 10 years at a single institution. Prof Neil Merrett, University of Western Sydney, Sydney. November 2011.
Impact of mitochondrial genetic variation on the evolution of human cancers. Rae-Anne Hardie, Garvan Institute of Medical Research, Sydney. October 2011.
Characterisation of homologous recombination mutations in DNA of pancreatic cancer patients. Dr Jeremy Humphris, Garvan Institute of Medical Research, Sydney. October 2011.
The role of the class III histone deacetylase SIRT2 in Myc-induced malignancies. Tao Liu, ChildrenÕs Cancer Institute Australia for Medical Research, Sydney. September 2011.